Current status of immunisation for herpes zoster
Herpes zoster (HZ) is increasingly common in the aging and is experienced by approximately one in three people in their lifetime. It is also relatively common in immune-compromised people. Acute HZ causes severe pain, reduced quality of life and severe complications, including prolonged pain, or pos...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2445384 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841557058273411072 |
|---|---|
| author | Anthony Lawrence Cunningham Kerrie Jane Sandgren Janette Taylor |
| author_facet | Anthony Lawrence Cunningham Kerrie Jane Sandgren Janette Taylor |
| author_sort | Anthony Lawrence Cunningham |
| collection | DOAJ |
| description | Herpes zoster (HZ) is increasingly common in the aging and is experienced by approximately one in three people in their lifetime. It is also relatively common in immune-compromised people. Acute HZ causes severe pain, reduced quality of life and severe complications, including prolonged pain, or postherpetic neuralgia (PHN), and ocular zoster, which may rarely progress to blindness. In severely immune-compromised people disseminated zoster may affect the brain and liver. A second-generation vaccine, the Recombinant Zoster Vaccine, consisting of recombinant viral glycoprotein E and the Adjuvant System 01 (AS01B), now offers >90% efficacy against HZ and associated complications in immune-competent people. Efficacy persists above 80% for 11 years. In severely immune-compromised patients, the vaccine is safe with efficacy and/or immunogenicity of 68–87%. There is also excellent immunogenicity for those on JAK inhibitors and corticosteroid therapy. The vaccine offers a paradigm for successful and durable immunization in the aging and immune-compromised. |
| format | Article |
| id | doaj-art-e9e1278ff1bc4fceb6d26caa3c32903f |
| institution | Kabale University |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-e9e1278ff1bc4fceb6d26caa3c32903f2025-01-07T00:05:28ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2025-12-0121110.1080/21645515.2024.2445384Current status of immunisation for herpes zosterAnthony Lawrence Cunningham0Kerrie Jane Sandgren1Janette Taylor2Centre for Virus Research, The Westmead Institute for Medical Research, Westmead, NSW, AustraliaCentre for Virus Research, The Westmead Institute for Medical Research, Westmead, NSW, AustraliaCentre for Virus Research, The Westmead Institute for Medical Research, Westmead, NSW, AustraliaHerpes zoster (HZ) is increasingly common in the aging and is experienced by approximately one in three people in their lifetime. It is also relatively common in immune-compromised people. Acute HZ causes severe pain, reduced quality of life and severe complications, including prolonged pain, or postherpetic neuralgia (PHN), and ocular zoster, which may rarely progress to blindness. In severely immune-compromised people disseminated zoster may affect the brain and liver. A second-generation vaccine, the Recombinant Zoster Vaccine, consisting of recombinant viral glycoprotein E and the Adjuvant System 01 (AS01B), now offers >90% efficacy against HZ and associated complications in immune-competent people. Efficacy persists above 80% for 11 years. In severely immune-compromised patients, the vaccine is safe with efficacy and/or immunogenicity of 68–87%. There is also excellent immunogenicity for those on JAK inhibitors and corticosteroid therapy. The vaccine offers a paradigm for successful and durable immunization in the aging and immune-compromised.https://www.tandfonline.com/doi/10.1080/21645515.2024.2445384Herpes zosterrecombinant zoster vaccineadjuvantprotein vaccineagingimmune-compromised |
| spellingShingle | Anthony Lawrence Cunningham Kerrie Jane Sandgren Janette Taylor Current status of immunisation for herpes zoster Human Vaccines & Immunotherapeutics Herpes zoster recombinant zoster vaccine adjuvant protein vaccine aging immune-compromised |
| title | Current status of immunisation for herpes zoster |
| title_full | Current status of immunisation for herpes zoster |
| title_fullStr | Current status of immunisation for herpes zoster |
| title_full_unstemmed | Current status of immunisation for herpes zoster |
| title_short | Current status of immunisation for herpes zoster |
| title_sort | current status of immunisation for herpes zoster |
| topic | Herpes zoster recombinant zoster vaccine adjuvant protein vaccine aging immune-compromised |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2445384 |
| work_keys_str_mv | AT anthonylawrencecunningham currentstatusofimmunisationforherpeszoster AT kerriejanesandgren currentstatusofimmunisationforherpeszoster AT janettetaylor currentstatusofimmunisationforherpeszoster |